-
Mashup Score: 36Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas - 23 hour(s) ago
For more than 70 years, glucocorticoids have been known to have clinical activity against lymphoid but not myeloma malignancies. Choi et al. resolve this conundrum by demonstrating that glucocorticoids kill lymphomas by inhibiting BCR signaling. These mechanistic insights enable rational combination of glucocorticoids with other targeted agents in anti-lymphoma regimens.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 44
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women MD-PhD physician scientists are less likely to serve as principal investigators on mid- and later careers awards. Here, Steinman et al. discuss the causes of gender disparities in academic medicine, the implications of losing highly trained women physician scientists, and the institutional and systemic changes needed to sustain this pool of talented investigators.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 44
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women MD-PhD physician scientists are less likely to serve as principal investigators on mid- and later careers awards. Here, Steinman et al. discuss the causes of gender disparities in academic medicine, the implications of losing highly trained women physician scientists, and the institutional and systemic changes needed to sustain this pool of talented investigators.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 44
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women MD-PhD physician scientists are less likely to serve as principal investigators on mid- and later careers awards. Here, Steinman et al. discuss the causes of gender disparities in academic medicine, the implications of losing highly trained women physician scientists, and the institutional and systemic changes needed to sustain this pool of talented investigators.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 93
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung cancer (NSCLC) management. Identifying the optimal treatment pattern—whether it’s neoadjuvant, adjuvant, or a combination of both—is a crucial next step, particularly in pinpointing which patients benefit the most. This decision-making process requires a multi-disciplinary treatment team capable of utilizing tissue and plasma genomic testing to inform therapeutic choices. Leveraging the perioperative treatment platform, it remains pivotal to integrate circulating tumor DNA (ctDNA) monitoring into clinical trial design efficiently and provide clear guidance on treatment.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 34Home – Hallmarks of Cancer - 3 day(s) ago
Hallmarks of Cancer
Source: www.cell-symposia.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 108
Diepstraten et al. demonstrate that p53 enforces apoptosis induced by BH3-mimetic drugs. To boost BH3-mimetic-induced apoptosis in TP53-mutant blood cancers, STING agonists were employed to induce pro-apoptotic BH3-only protein expression in a p53-independent manner. Therefore, BH3-mimetics alongside STING agonists represents a promising new combination therapy for aggressive TP53-mutant blood cancers.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 106
The increasing number of approved treatment combinations for metastatic renal cell carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this issue of Cancer Cell, Saliby et al. validate the distinct clinico-genomic profiles of expression-based molecular clusters identified in the IMmotion151 trial in the JAVELIN Renal 101 dataset.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 154
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2 deficiency boosts oxidative phosphorylation activity, prompting lipid-laden CAF formation through BMP2 signaling, offering promising therapeutic avenues in personalized cancer treatment.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 209
Tumor-associated macrophages (TAMs) are well known to fuel tumor evolution. Blériot et al. advocate for integrating the time dimension when conceptualizing macrophage diversity in pre-malignancy and cancer and propose the term “PreTAMs” to emphasize their early roles in orchestrating inflammatory responses that often precede, and not just result from, tumor onset.
Source: www.cell.comCategories: General Medicine News, Onc News and JournalsTweet
Online Now: Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas https://t.co/IhAOMWYi3g https://t.co/fs6dNm7f1U